Medtronic (MDT) stock fell by 1.53% due to concerns arising from Orchestra BioMed's public offering of shares, which may lead to dilution for existing shareholders.

Medtronic (MDT) stock fell by 1

Medtronic's stock (MDT) declined by 1.53% following its announcement of a $30 million investment in Orchestra BioMed to support the development of AVIM therapy-enabled leadless pacemakers, amidst concerns over the financial implications of such investments and potential market reactions.

Medtronic's stock (MDT) declined by 1

Medtronic (MDT) stock rose 0.51% amid broader market trends influenced by consumer goods companies like Procter & Gamble, which announced price hikes due to tariffs, signaling potential inflation and cost-passing to consumers that could impact market dynamics.

Medtronic (MDT) stock rose 0

Medtronic (MDT) stock fell by 1.04% following Mizuho's adjustment of price targets in the medical devices sector ahead of its Q2 earnings reports, even as the company reported solid revenue growth and earnings for FY25.

The article discusses the bullish outlook on Medtronic plc (MDT) stock, which is currently characterized by strong fundamentals, a solid dividend history, and anticipated revenue growth, leading to a 0.34% increase in the stock price. Medtronic's stock went up due to its reliable dividend yield, stable financial performance, significant investments in innovation, and strong institutional support, which bolster confidence in its long-term growth potential.

The article discusses the bullish outlook on Medtronic plc (MDT) stock, which is currently character

Medtronic (MDT) stock recently rose by 0.34% due to ongoing positive sentiment from its planned spin-off of the diabetes unit, which is expected to unlock value for investors and has contributed to an overall appreciation of approximately 10.96% since the announcement.

Medtronic (MDT) stock recently rose by 0

Medtronic (MDT) stock rose by 0.39% due to increased institutional interest, as several hedge funds bolstered their positions in the company, reflecting growing confidence in its financial performance and future prospects.

Medtronic (MDT) stock rose by 0

The article discusses the concept of creating a "Weekly Paycheck Portfolio" composed of dividend-paying stocks, highlighting Medtronic (MDT) as one of the options due to its strong market position and consistent dividend yield, which is likely a reason for its recent 0.1% stock increase. 

Medtronic's stock may go up due to its solid performance in medical technology markets and the approval of AI-enabled devices, coupled with its reputation as a reliable dividend payer amid potential for future growth.

The article discusses the concept of creating a "Weekly Paycheck Portfolio" composed of dividend-pay

Medtronic (MDT) stock fell by 0.28% despite a generally positive consensus rating from analysts, likely due to market fluctuations and investor reactions following their recent earnings report and dividend announcement.

Medtronic (MDT) stock fell by 0

Medtronic (MDT) stock saw a slight decline of 0.21%, attributed to fluctuating trading volumes and the general market conditions affecting energy stocks, as noted by MarketBeat News.

Medtronic (MDT) stock saw a slight decline of 0

The article discusses the appointment of Martha Aronson as the new President and CEO of Merit Medical Systems, Inc., effective October 3, 2025, and announces preliminary unaudited revenue results for the second quarter of 2025, indicating an expected increase year-over-year.

Medtronic (MDT) stock likely declined by -0.81% due to market reactions influenced by sector performance, investor sentiment, or broader economic factors rather than specific news related to Medtronic itself, as the article focuses on Merit Medical's leadership changes and financial performance.

The article discusses the appointment of Martha Aronson as the new President and CEO of Merit Medica

Medtronic (MDT) stock decreased by 0.53% following a series of downgrades on target prices by various brokerages, which potentially affected investor sentiment despite an upgrade from Wolfe Research.

Medtronic (MDT) stock decreased by 0

Medtronic (MDT) stock increased by 1.81% last night, likely due to rising demand for skilled CFOs and the related stability in compensation trends for CFOs, reflecting broader investor optimism in the healthcare sector amidst economic challenges.

Medtronic (MDT) stock increased by 1

Medtronic (MDT) stock fell by 0.13% due to institutional investors adjusting their positions, with some cutting their stakes and analysts lowering price targets, indicating potential concerns about the stock’s future performance.

Medtronic (MDT) stock fell by 0.44% following a report indicating that PFG Investments LLC reduced its holdings in the company, along with other institutional investment activity, which may have contributed to negative investor sentiment.

Medtronic (MDT) stock fell by 0.51% amid mixed earnings forecasts and analyst ratings, with standout estimates predicting slight revenue growth but accompanied by price target adjustments by some analysts. 

The decline in Medtronic's stock price may have been influenced by revised price targets from analysts and varying ratings, which could create uncertainty among investors despite an overall positive earnings outlook.

Medtronic (MDT) stock declined by 0.51% amidst mixed analyst ratings and price target adjustments, with some upgrades suggesting potential upside and others indicating a more cautious outlook, contributing to market uncertainty about its future performance.

Medtronic (MDT) stock declined by 0

Medtronic (MDT) stock decreased by 1.99% due to a reduction in holdings by Sound Income Strategies LLC and mixed analyst ratings following its recent earnings report, which indicated modest growth despite better-than-expected earnings.

Medtronic (MDT) stock decreased by 1

Medtronic (MDT) stock fell by 1.99% due to factors affecting the broader healthcare technology market, including increased competition and market dynamics related to diabetic retinopathy advancements, as well as potential investor concerns surrounding its recent corporate restructuring plans with the establishment of its new diabetes-focused entity named MiniMed.

Medtronic (MDT) stock declined by -1.99%, influenced by overall market conditions and competitive pressures in the healthcare sector, despite a positive initiation of coverage by Leerink which highlighted growth potential in its Cardiac Ablation Solutions business and other strategic shifts.

Medtronic (MDT) stock declined by -1

Medtronic (MDT) stock fell by -1.38% due to concerns about the efficacy and safety of their intravenous iron therapy (ferric derisomaltose) for heart failure patients, particularly regarding its effects across different age groups in the recent IRONMAN trial, which showed no significant benefits for older patients compared to younger counterparts.

Medtronic (MDT) stock fell by -1

The article discusses how Medtronic (MDT) stock experienced a slight increase of 0.01%, driven primarily by positive market trends and investor sentiment.

The article discusses how Medtronic (MDT) stock experienced a slight increase of 0

The article discusses the research and developments related to adherent invasive Escherichia coli (AIEC) and its association with Crohn's disease, highlighting a recent international meeting on the topic. Medtronic (MDT) stock likely rose by 1.64% due to positive market sentiment, possibly linked to ongoing advancements in medical technologies or therapies related to conditions like Crohn's disease, although the article primarily focuses on AIEC research rather than stock analysis.

The article discusses the research and developments related to adherent invasive Escherichia coli (A

Medtronic's (MDT) stock experienced a slight increase of 0.07% as analysts favor it over Xcorporeal due to its stronger revenue, earnings, and institutional ownership, along with a positive consensus price target suggesting potential for further growth.

Medtronic's (MDT) stock experienced a slight increase of 0

The article discusses a meta-analysis comparing the effectiveness of P2Y12 inhibitor monotherapy to aspirin monotherapy in patients who have undergone percutaneous coronary intervention (PCI), finding that the former is associated with a lower risk of major adverse cardiac and cerebrovascular events without an increase in major bleeding risk. Medtronic (MDT) stock may have risen by 0.07% due to positive sentiment around advancements in cardiovascular treatments, potentially increasing investor confidence in companies involved in this sector, including Medtronic, which develops related medical devices.

The article discusses a meta-analysis comparing the effectiveness of P2Y12 inhibitor monotherapy to 

Medtronic (MDT) stock rose 2.15% following Representative Robert Bresnahan, Jr.'s purchase of shares and the company's strong quarterly earnings report, which exceeded analyst expectations.

Medtronic (MDT) stock rose 2

The article discusses Medtronic (MDT) stock rising by 1.44% last night, although it mainly focuses on Elon Musk's recent government activities and business deals rather than on Medtronic directly. Medtronic stock may be positively influenced by overall market trends, positive investor sentiment, or company-specific developments such as product news or earnings forecasts, though the article does not provide specific reasons for its increase.

The article discusses Medtronic (MDT) stock rising by 1

Medtronic (MDT) stock saw a slight increase of 0.07% following Boston Scientific's decision to discontinue its competing heart-valve replacement systems, which positively impacted the market for rival companies like Medtronic.

Medtronic (MDT) stock saw a slight increase of 0

Medtronic (MDT) stock increased by 0.62% due to significant investments by institutional investors and positive earnings reports exceeding expectations.

Medtronic (MDT) stock increased by 0

Medtronic (MDT) stock rose by 0.62% following strong quarterly earnings that exceeded analysts' expectations, which likely boosted investor confidence despite some mixed ratings and target price adjustments by various analysts.

Medtronic (MDT) stock fell by 0.28%, closing at $85.35, likely due to general market pressures affecting AI stocks and the healthcare sector, despite the company maintaining solid financial metrics.

Medtronic (MDT) stock fell 4.15% following the announcement of its plan to separate its diabetes business into a standalone entity within 18 months, primarily due to concerns over future performance and investor reactions to the operational challenges faced by the diabetes unit, including a recent FDA recall.

Medtronic (MDT) stock fell 4

Medtronic (MDT) experienced a -4.15% stock decline due to a significant increase in put options trading, indicating investor concerns, despite the company reporting better-than-expected earnings and a dividend increase.

Medtronic (MDT) experienced a -4

Medtronic's stock declined by 2.27% because, despite exceeding earnings forecasts, the company announced plans to spin off its diabetes business, which raised concerns among investors.

Medtronic's stock declined by 2

Medtronic (MDT) stock declined by 2.27% last night, likely due to broader market fluctuations and investor reactions to unfavorable economic news or company-specific concerns.

Medtronic (MDT) stock declined by 2

Medtronic's stock fell by 2.27% after the announcement of its plan to spin off its struggling diabetes business into a new public company, which investors may perceive as a reduction in future growth potential for Medtronic.

Medtronic's stock fell by 2

Medtronic (MDT) stock declined by 0.69% as several analysts maintained a "hold" rating, reflecting mixed sentiments about the company's performance and future prospects, particularly after it reported revenues slightly below analysts' expectations in its latest earnings results.

Medtronic (MDT) stock rose by 0.61% ahead of its anticipated Q4 2025 earnings announcement, which is expected to show strong earnings and revenue growth that surpasses analyst estimates. The stock's increase can be attributed to positive investor sentiment driven by the company's projected earnings, recent institutional investment activities, and favorable analyst ratings despite mixed opinions on target prices.

Medtronic (MDT) stock rose by 0.61% likely due to positive historical trends indicating favorable returns following earnings announcements, as well as strong consensus estimates for upcoming earnings exceeding those from the previous year.

Medtronic (MDT) stock rose 0.38% as positive sentiments emerged surrounding a truce in U.S.-China trade tensions, leading to increased investment eagerness among CEOs amidst an uncertain market landscape.

Medtronic (MDT) stock rose 0.38% likely due to overall positive market sentiments and optimism surrounding upcoming earnings reports that may indicate resilience in sectors including healthcare, following a generally favorable outlook from investors discussed by CNBC's Jim Cramer.

The article discusses the recent rise of Critical Metals Corp's stock, which was up by 1.54%, following the appointment of several key executives and a binding agreement with major shareholders to secure their holdings for 180 days, signaling confidence in the company's strategic projects in the critical minerals sector. Medtronic (MDT) stock likely increased due to positive market sentiment and developments in management that could boost investor confidence in Critical MetalsCorp’s plans.

Headline	Summary	Source
Medtronic (MDT) stock fell by 1	Medtronic (MDT) stock fell by 1.53% due to concerns arising from Orchestra BioMed's public offering of shares, which may lead to dilution for existing shareholders.	Globenewswire
Medtronic's stock (MDT) declined by 1	Medtronic's stock (MDT) declined by 1.53% following its announcement of a $30 million investment in Orchestra BioMed to support the development of AVIM therapy-enabled leadless pacemakers, amidst concerns over the financial implications of such investments and potential market reactions.	Globenewswire

MDT

Latest News & Analysis